Rivastigmine Patch Suppliers & Bulk Manufacturers
Available Forms: Transdermal patches
Available Strengths: 4.6 mg/24 hr and 9.5 mg/24 hr patches
Reference Brands: Exelon
Category:
Transdermal Patches
Rivastigmine patches inhibit acetylcholinesterase, increasing acetylcholine levels in the brain. This improves cognitive function, slows dementia progression, and reduces symptoms in Alzheimer’s and Parkinson’s disease. Benefits include steady drug delivery, enhanced compliance, fewer gastrointestinal side effects, and improved quality of life for patients with cognitive decline.
Rivastigmine Patch is available in Transdermal patches
and strengths such as 4.6 mg/24 hr and 9.5 mg/24 hr patches.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Rivastigmine Patch is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Rivastigmine Patch can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Rivastigmine patches are regulated in the EU and US, supported by dossiers demonstrating safety, efficacy, and manufacturing quality per GMP standards. In the US, FDA approval involved clinical validation, safety assessments, and GMP compliance. In the EU, CE marking certifies conformity with MDR standards. These devices undergo validation, stability testing, and audits, with comprehensive documentation including safety profiles, clinical data, and manufacturing practices. For licensing procedures, approved dossiers, and the latest regulatory updates, visit Pharmatradz. Ensuring regulatory compliance guarantees access to reliable, effective rivastigmine transdermal systems, supporting improved management of dementia symptoms worldwide and facilitating safe, regulated treatment options for patients with cognitive decline.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing